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Abstract
Aims/hypothesis The extent to which effects of BMI on CHD
are mediated by glycaemic and lipid risk factors is unclear. In
this study we examined the effects of these traits using genetic
evidence.
Methods We used two-sample Mendelian randomisation to
determine: (1) the causal effect of BMI on CHD (60,801 case
vs 123,504 control participants), type 2 diabetes (34,840 case
vs 114,981 control participants), fasting glucose (n = 46,186),
insulin (n = 38,238), HbA1c (n = 46,368) and LDL-cholesterol,
HDL-cholesterol and triacylglycerols (n = 188,577); (2) the
causal effects of glycaemic and lipids traits on CHD; and (3) the
extent to which these traits mediate any effect of BMI on CHD.
Results One SD higher BMI (~ 4.5 kg/m2) was associated
with higher risk of CHD (OR 1.45 [95% CI 1.27, 1.66]) and
type 2 diabetes (1.96 [95% CI 1.35, 2.83]), higher levels of
fasting glucose (0.07 mmol/l [95% CI 0.03, 0.11]), HbA1c
(0.05% [95% CI 0.01, 0.08]), fasting insulin (0.18 log pmol/l
[95% CI 0.14, 0.22]) and triacylglycerols (0.20 SD [95% CI
0.14, 0.26]) and lower levels of HDL-cholesterol (−0.23 SD
[95% CI −0.32, −0.15]). There was no evidence for a causal
relation between BMI and LDL-cholesterol. The causal
associations of higher triacylglycerols, HbA1c and diabetes
risk with CHD risk remained after performing sensitivity
analyses that considered different models of horizontal
pleiotropy. The BMI–CHD effect reduced from 1.45 to 1.16
(95% CI 0.99, 1.36) and to 1.36 (95% CI 1.19, 1.57) with
genetic adjustment for triacylglycerols or HbA1c, respectively,
and to 1.09 (95% CI 0.94, 1.27) with adjustment for both.
Conclusions/interpretation Increased triacylglycerol levels
and poor glycaemic control appear to mediate much of the
effect of BMI on CHD.
Keywords Bodymass index . Cardiovascular disease risk
factors . Coronary heart disease . Mediation .Mendelian
randomisation
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Introduction
Greater BMI is a risk factor for a wide range of adverse health
outcomes, including CHD the leading cause of death
worldwide. Whilst preventing overweight and obesity is an
important public health aim, the substantial and increasing
number of people with a high BMI highlights the need for
secondary prevention that aims to reduce risk of the main
disease outcomes of high BMI, such as CHD, by targeting
causal mediators. This is also important because beyond
bariatric surgery there are no effective and sustainable treat-
ments for those who are obese [1].
Large prospective population studies show that higher BMI
is associated with adverse blood lipid levels, higher fasting
glucose and insulin, type 2 diabetes mellitus and CHD.
RCTs show that elevated triacylglycerols, LDL-cholesterol,
glucose and BP increase the risk of CHD [2, 3]. Thus, the
association of BMI with CHD could be mediated by these
established modifiable risk factors. However, the common
method used to test for mediation, by observing how much
the confounder-adjusted multivariable association between a
risk factor (e.g. BMI) and outcome (e.g. CHD) reduces with
further adjustment for potential mediators [4], has been shown
to be biased in many situations [5].
Mendelian randomisation (MR), the use of genetic variants
as instrumental variables to test the causal effect of risk factors
on outcomes, is unlikely to be biased by the extensive
confounders of multivariable observational analyses, is less
prone to measurement error [6] and, because genetic variants
are fixed at conception, cannot be biased by reverse causality
[7, 8]. As such, MR has been used increasingly over the past
decade to provide more robust estimates for the causal effect
of many risk factors on a range of health outcomes, with
results from MR closely resembling those from RCTs where
both are available (e.g. the effect of LDL-cholesterol [9] and
systolic BP [10] on CHD). Recently, methods have been
developed for its use in testing causal mediation using a
two-step approach that is considerably less prone to the
biases inherent in the common multivariable approach [5].
Figure 1 provides a brief description of MR and its
assumptions.
PreviousMR studies using data from three collections have
shown that higher BMI causally relates to higher risk for CHD
(the results of our meta-analysis of these previous MR studies
are presented in the electronic supplementary material [ESM]
Fig. 1) [11–14]. These studies used one-sample MR and were
unable to undertake sensitivity analyses that have been
developed for testing likely bias by pleiotropy [15]. The
number of cases of CHD varied from 3062 to 11,056, which
are modest for MR studies. Although MR is likely to be less
biased than conventional multivariable approaches, it usually
requires a considerably larger sample size. Only one of these
MR studies analysed potential mediators of the impact of BMI
on CHD. It concluded that LDL-cholesterol, remnant
cholesterol and systolic BP, explained 8%, 7% and 7%,
respectively, of the effect of BMI on CHD [14]. That study
was unable to explore potential mediation by insulin
sensitivity or hyperglycaemia, which are strongly influenced
by BMI and are strong risk factors for CHD. Here, we aimed
to investigate the mediating effects of lipid and insulin/
glycaemic traits on the effect of BMI on CHD using a large
MR study, including over 60,000 individuals with CHD, and
to analyse a wider set of potential mediators including
glycaemic traits (fasting glucose and insulin, HbA1c, type 2
diabetes) than previous studies.
Methods
We used two-step two-sample MR [5, 16] with publicly
available datasets that provide genome-wide association
results for BMI, glycaemic traits, lipids and CHD.
Two-sample MR refers to the use of different datasets
(samples) to obtain the gene–risk factor (e.g. BMI) and
gene–outcome (e.g. CHD) associations. First, we tested the
effects of BMI on CHD, and then the effects of potential
mediation using two-step MR. In step one we tested causal
effects of BMI on potential mediators and in step two the
causal effects of potential mediators on CHD [5].
Data sources
Genetic instrumental variable for BMI From the most
updated genome-wide associations studies (GWAS) on BMI,
the Genetic Investigation of ANthropometric Traits (GIANT)
consortium, we obtained 77 SNPs, identified from the primary
meta-analysis of 322,154 European-descent individuals,
independently contributing to BMI at genome-wide
significance (p < 5 × 10−8) [17]. These variants were defined
as being independent of each other on the basis of low
correlation (R2 < 0.1) in HapMap22 or the 1000 Genome
project data. These 77 SNPs account for 2.4% of BMI
phenotypic variance [17]. For sensitivity analyses, we
included 20 SNPs from the secondary analysis of this
GWAS [17]; these include some SNPs that did not reach
genome-wide significance in Europeans.
Potential mediators Associations of SNPs with the
phenotypes were extracted from publicly available GWAS
consortia. Data on type 2 diabetes mellitus GWAS correlates
was obtained from the DIAbetes Genetics Replication And
Meta-analysis (DIAGRAM, http://diagram-consortium.org/
downloads.html, accessed on 22 June 2016), which includes
34,840 case and 114,981 control participants of European
origin [18]. Genetic associations with fasting insulin
(n = 38,238), fasting glucose (n = 46,186) and HbA1c
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(n = 46,368) were obtained from the Meta-Analyses of
Glucose and Insulin-related traits Consortium (MAGIC,
http://www.magicinvestigators.org/, accessed on 22
June 2016); the participants were of European ancestry
without diabetes [19]. Genetic associations with HDL-
cholesterol, LDL-cholesterol and triacylglycerols in 188,577
Europeans were obtained from the Global Lipids Genetics
Consortium (GLGC) investigators (http://csg.sph.umich.edu/
abecasis/public/lipids2013/, accessed on 22 June 2016) [20].
Study outcome: CHD Data on coronary artery disease/
myocardial infarction were obtained from the Coronary
ARtery DIsease Genome wide Repl ica t ion And
Meta-analysis (CARDIoGRAM) plusC4D investigators
(www.CARDIOGRAMPLUSC4D.ORG, accessed on 22
June 2016) [21]. This includes 60,801 CHD case and
123,504 control participants. We first searched the
CARDIoGRAMplusC4D 1000 Genomes-based GWAS, a
meta-analysis of GWAS studies of mainly European, South
Asian and East Asian descent imputed using the 1000
Genomes phase 1 v3 training set with 38 million variants
[22]. If no summary data on the gene–CHD association were
found from the 1000 Genomes data, then we screened in
CARDIoGRAMplusC4D Metabochip. If the targeted SNPs
were not found in either the 1000 Genomes or the
CARDIoGRAMplusC4D Metabochip, we then screened
CARDIoGRAM GWAS.
The genetic variants used as instrumental variables for
CHD, BMI and CHD risk factors (potential mediators) are
all shown in ESM Tables 1–9.
Statistical analysis
As an indication of the strength of the association between
genetic instruments and phenotypes, we report the proportion
of variation in BMI and all mediators explained by their
genetic variant instruments and also the F-statistic for the
regression of BMI and all mediators on their genetic
instruments. The proportion of the BMI–CHD effect that is
explained by a group of mediators will be estimated with bias
if the mediators are related to each other, and/or if the outcome
has an effect on the mediator (i.e. there is reverse causality)
and the instrument affects the mediators through the outcome.
Therefore, we tested for potential bi-directional causal effects
of BMI, potential mediators and CHD with each other using
the inverse variance weighted (IVW) approach described
below.
Horizontal pleiotropy, where the genetic variant influences
the outcome through a pathway other than the exposure,
violates an assumption of MR and can bias causal estimates.
To guard against this we used three different analytical
approaches for both step one (effect of BMI on CHD and
potential mediators) and step two (effect of potential
mediators on CHD) of the two-step MR mediation approach.
Potential confounders
Outcome of 
interest
(e.g. CHD)
Genetic instrumental variable 
(e.g. weighted allele score of 
genetic variants robustly 
associated with BMI)
Risk factor of 
interest 
(e.g. BMI)
Fig. 1 Summary of MR and its assumptions. The underlying
assumptions of MR are that: (1) the genetic instrumental variable(s) are
robustly related to the risk factor of interest (here BMI; this is illustrated
by the arrow from the genetic instruments to BMI); (2) there is no
relationship between any confounders of the risk factor (BMI) and
outcome (CHD) and the genetic instrumental variable (illustrated by the
lack of any arrow between these confounders and the genetic instrument);
and (3) there is no path from the genetic instrument to the outcome other
than through its relationship to the risk factor (illustrated by the lack of
any arrow that goes directly from the genetic instrument to the outcome).
Empirical evidence suggests that the most likely of these three
assumptions to be violated, and result in potentially biased results, is the
last one. This may be violated inMR studies by horizontal pleiotropy (i.e.
where the genetic instrument[s] affect other factors which, independent of
their impact on the risk factor of interest, influence the outcome). If this
horizontal pleiotropy is present then theMR estimate of the effect of a risk
factor on outcomewill be biased, it will actually be the combined effect of
that risk factor and any other (pleiotropic) paths from the genetic
instruments to outcome. The bias could be an exaggeration of the true
effect (if the horizontal pleiotropic paths are in the same direction as that
of the main risk factor of interest) or a diminution of the true effect (if the
horizontal pleiotropic effect is in the opposite direction of the risk factor
of interest). There are a number of different statistical methods that can be
used to estimate causal MR effects. Many of these are related to the ratio,
which is intuitive. If the assumptions above are correct then the causal
effect of the risk factor (BMI) on outcome (CHD) is the ratio of ‘the
association of genetic instruments with CHD’ to ‘the association of
genetic instrument with BMI’. Valid MR estimates can be obtained using
two (independent) samples for the association of the genetic instrument
with outcome and the association of genetic instrument with risk factor
[16]. There are some advantages of this two-sample MR approach over
the one-sample approach (where both parts of the ratio are obtained from
the same sample), including the potential to gain very large sample sizes
by using publicly available aggregate genome-wide data as we have done
here and apply novel methods for testing horizontal pleiotropy that have
been developed for use in two-sample MR with aggregate GWAS data
(see the Methods section and the ESM for detailed descriptions of these)
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Each of the three methods assumes different models of
horizontal pleiotropy. The value of comparing results from
all three is that we have more confidence in results that are
consistent across the different methods. Full details of these
approaches, including their different assumptions, are
provided in Table 1 and ESM Methods 1.
To estimate the effect of BMI on CHD taking account of
genetically determined potential mediators, we used the IVW
MR method, adjusting for the SNP–potential mediator effect
[23]. The proportion of the effect that is mediated by any of
the potential mediators was estimated by the changes in the
total effect of the genetically determined BMI on CHD risk
(for more details see ESM Methods 2). This method assumes
that mediators are continuously measured variables and as
type 2 diabetes is dichotomised we did not assess the
proportion of the BMI–CHD effect due to type 2 diabetes.
An analysis diagram is shown in Fig. 2. All statistical analysis
was performed using STATA 13.1 (Stata Corp LP, College
Station, TX, USA) and R (version 3.2.5, the R Foundation
for statistical Computing, Vienna, Austria) software.
Results
The proportion of variation explained by all of the variants
that we used as instrumental variables for the potential
mediators varied from 1.2% (for fasting insulin) to 5.7% (for
type 2 diabetes) (ESM Tables 1–8). The first stage F-statistic
for all of the MR analyses (i.e. for the regression of BMI and
each of the mediators on their genetic variant instrument
variables) were very large (> 500).
Relationships between potential mediators and CHD
As expected, we observed evidence for association between
fasting plasma glucose and type 2 diabetes, and that both
fasting plasma glucose and type 2 diabetes were associated
with HbA1c (Table 2). LDL-cholesterol, HDL-cholesterol
and triacylglycerols were associated with each other. CHD
appears to be causally positively related to type 2 diabetes,
but was not related to other potential mediators (Table 2).
Effects of BMI on CHD and glycaemic and lipid traits
There was consistent support across all three MR methods for
a causal effect of higher BMI on higher CHD and type 2
diabetes risk, and higher levels of fasting glucose, HbA1c,
fasting insulin and triacylglycerols, together with lower
HDL-cholesterol (Table 3). None of the methods supported
a causal effect of BMI on LDL-cholesterol (Table 3 and
ESM Table 10).
Effects of potential mediators on CHD
There was broadly consistent support across all three MR
methods for a positive effect of type 2 diabetes, HbA1c,
Table 1 Summary of the three methods used for MR analysis
IVW Weighted-median MR-Egger
Assumption All genetic instrumental variables are valid
or any horizontal pleiotropic effects of
instruments are balanced
No more than 50% of the weight of the
estimate is from invalid genetic
instrumental variables
No single instrumental variable contributes
>50% of the weight
InSIDE (instrument strength independent of
direct effect) assumption, which states
that the effect of the instrument on the
exposure is not correlated with any direct
effect of the instrument on the outcome
Equation
β^IVW ¼ ∑
K
K¼1EkDkσ
−2
Dk
∑KK¼1E
2
kσ
−2
Dk
SE
β^IVW¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
∑k
k¼1E
2
K
σ−2
Dk
q
EK is the mean change in exposure level per
additional effect allele of SNP k;Dk is the
mean change in disease outcomes (e.g.
log odds of CHD or levels of other
cardiovascular disease risk factors) per
additional effect allele of SNP k with SE
σDk
Weighted-median estimator is the median of
a distribution having estimate βj as:
Pj = 100(Sj − Wj/2)th percentile
P is the percentile for the jth ordered ratio
estimate; Wj is the weight given to the j
th
ordered ratio estimate, proportional to the
inverse of the instrumental variable
variance, and Sj is the sum of weights up
to and including the weight of the jth
ordered ratio estimates, calculated using
the following equation:
Sj ¼ ∑ jK¼1Wk
MR-Egger uses a weighted linear regression
of the gene–outcome coefficients θj on
the gene–exposure coefficients δj:
θj = β0E + βE × δj
All the δj associations are orientated to be
positive. If β0E is truly zero (or were
constrained to be zero) the MR-Egger
slope estimate βE is the same as the β
from IVW
Application The IVW estimate is a statistically efficient
method but it can be biased even if just
one genetic variant is invalid (i.e. if just
one variant has horizontal pleiotropic
effects)
The weighted-median estimator is a
modification of the simple median
approach and takes account of the
variance of the individual genetic
instruments
The MR-Egger method is used to test for
directional horizontal pleiotropy and
correct for this in MR analyses
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triacylglycerols and LDL-cholesterol on CHD risk (Table 4).
For type 2 diabetes the MR-Egger 95% CI just included the
null value, but this method has lower statistical power than the
others and the point estimates were similar across all methods.
For triacylglycerols the estimate of effect (slope) from
MR-Egger was a little weaker than for all of the other methods
(e.g. 1.24 vs 1.13 comparing the IVW and MR-Egger
methods), suggesting that some but not all of the effect of
triacylglycerols estimated by IVW and other methods might
be due to horizontal pleiotropy. In IVW and the median
method analyses, there is evidence for the causal association
of lower HDL-cholesterol and higher fasting glucose and
insulin with higher risk of CHD. However, for all of these
MR-Egger suggested that effects were largely due to
horizontal pleiotropy, with effect estimates markedly
attenuated to the null and the intercepts all being non-zero.
Mediating effects of lipids and glycaemic traits
on BMI–CHD effects
We explored those potential mediators that had causal support
from MR for both an effect of BMI on them (step one) and of
the mediators on CHD (step two): type 2 diabetes, HbA1c and
triacylglycerols (Table 5). Our results suggested that
triacylglycerols were an important mediator, with either type
2 diabetes or HbA1c further contributing to mediation of BMI
on CHD. The BMI–CHD effect reduced from 1.45 (95% CI
1.27, 1.66) to 1.16 (95% CI 0.99, 1.36) and 1.36 (95% CI
1.19, 1.57) with adjustment for the estimated effects of
triacylglycerols and HbA1c, respectively, and to 1.09
(95% CI 0.94, 1.27) with adjustment for both.
Discussion
This is the first paper to explore the extent to which glycaemic
traits mediate a causal path between BMI and CHD, whilst
using statistical approaches that account for horizontal
pleiotropy. Consistent with previous studies [11–14], but
using a larger sample size and more genetic variants, we show
that higher BMI causes greater CHD risk. Our results also
suggest that triacylglycerols, HbA1c and type 2 diabetes play
important roles in causally mediating the effect of BMI on
CHD. In contrast, our results do not support causal
effects for the observed association between BMI and
LDL-cholesterol, or for the associations of HDL-cholesterol,
fasting glucose or insulin with CHD. Secondary prevention,
which aims to reduce obesity-related CHD by targeting causal
mediators is important because of the large, and increasing,
proportions of people globally who are overweight or obese
and the lack, currently, of scalable effective treatments for
obesity. Treating causal mediators of the effect of BMI on
CHD could mitigate its effect, but biases in conventional
epidemiological methods for testing mediation have limited
GIANT SNP-BMI
MR analyses
Crude analysis
IVW, median-based
methods
Analysis accounting for 
horizontal pleiotropy 
(MR-Egger)
SNP-T2DM
MR analyses
Crude analysis
IVW, median-based
methods
Analysis accounting for 
horizontal pleiotropy 
(MR-Egger)Adjusted analysis 
(IVW method)
SNP-CHD
DIAGRAM
MAGIC
GLGC
CARDIoGRAM/
CARDIoGRAMplusC4D
SNP-FG/HbA1c/FI
SNP-LDL-C/HDL-C/TG
Fig. 2 Analysis diagram.
Summary data for SNP
phenotypes were extracted from
GWAS consortia datasets
(GIANT, CARDIoGRAM, C4D,
DIAGRAM, MAGIC and
GLGC). MR estimates of BMI on
mediators (type 2 diabetes
[T2DM], fasting glucose [FG],
fasting insulin [FI], HbA1c, LDL-
cholesterol [LDL-C], HDL-
cholesterol [HDL-C] and
triacylglycerols [TG]), and of
BMI and mediators on CHDwere
derived using the IVW method
2214 Diabetologia (2017) 60:2210–2220
T
ab
le
2
M
R
es
tim
at
es
a
of
ri
sk
fa
ct
or
s
on
ea
ch
ot
he
r
an
d
on
C
H
D
an
d
ty
pe
2
di
ab
et
es
O
ut
co
m
e
E
xp
os
ur
e
B
M
I,
S
D
T
2D
M
FP
G
,m
m
ol
/l
H
bA
1
c,
%
FI
,l
og
-p
m
ol
/l
L
D
L
-C
,S
D
H
D
L
-C
,S
D
T
G
,S
D
C
H
D
B
M
I,
SD
0
−0
.0
7
(0
.0
09
)*
**
0.
00
7
(0
.0
4)
0.
04
(0
.0
5)
−0
.5
1
(0
.1
4)
**
*
−0
.0
4
(0
.0
1)
*
0.
00
08
(0
.0
1)
−0
.0
04
(0
.0
2)
−0
.0
15
(0
.0
1)
T
2D
M
0.
67
(0
.1
9)
**
*
0
1.
23
(0
.1
4)
**
*
0.
36
(0
.2
)
0.
53
(0
.4
5)
−0
.0
9
(0
.0
6)
−0
.0
3
(0
.0
5)
0.
05
(0
.0
8)
0.
10
(0
.0
5)
*
FP
G
,m
m
ol
/l
0.
07
(0
.0
2)
**
*
0.
08
(0
.0
07
)*
**
0
0.
07
(0
.0
7)
0.
05
(0
.0
7)
−0
.0
4
(0
.0
1)
**
−0
.0
02
(0
.0
1)
−0
.0
1
(0
.0
2)
0.
01
(0
.0
1)
H
bA
1
c,
%
0.
05
(0
.0
3)
**
*
0.
03
(0
.0
1)
**
0.
45
(0
.0
4)
**
*
0
−0
.0
9
(0
.1
)
−0
.0
1
(0
.0
2)
−0
.0
2
(0
.0
2)
−0
.0
3
(0
.0
2)
0.
01
(0
.0
2)
H
bA
1
c,
m
m
ol
/m
ol
0.
55
(0
.3
3)
**
*
0.
33
(0
.1
1)
**
4.
92
(0
.4
4)
**
*
0
−0
.9
8
(1
.0
9)
−0
.1
1
(0
.2
2)
−0
.2
2
(0
.2
2)
−0
.3
3
(0
.2
2)
0.
11
(0
.2
2)
FI
,l
og
-p
m
ol
/l
0.
18
(0
.0
3)
**
*
0.
06
(0
.0
09
)*
**
0.
05
(0
.0
5)
−0
.0
6
(0
.0
6)
0
−0
.0
3
(0
.0
2)
0.
00
7
(0
.0
2)
0.
02
(0
.0
2)
−0
.0
08
(0
.0
1)
L
D
L
-C
,S
D
−0
.0
5
(0
.0
7)
0.
02
(0
.0
1)
0.
02
(0
.0
4)
0.
09
(0
.0
5)
0.
27
(0
.1
4)
*
0
−0
.2
1
(0
.0
2)
**
*
0.
19
(0
.0
3)
**
*
−0
.0
3
(0
.0
2)
H
D
L
-C
,S
D
−0
.2
3
(0
.0
4)
**
*
−0
.0
03
(0
.0
1)
0.
04
(0
.0
4)
0.
11
(0
.0
5)
*
0.
52
(0
.1
6)
**
*
−0
.1
8
(0
.0
2)
**
*
0
−0
.4
7
(0
.0
3)
**
*
−0
.0
2
(0
.0
2)
T
G
,S
D
0.
20
(0
.0
3)
**
*
0.
02
(0
.0
1)
0.
03
(0
.0
3)
−0
.0
2
(0
.0
5)
−0
.2
1
(0
.1
6)
0.
07
(0
.0
3)
*
−0
.1
6
(0
.0
1)
**
*
0
0.
00
1
(0
.0
2)
C
H
D
0.
37
(0
.0
7)
**
*
0.
10
(0
.0
3)
**
*
0.
19
(0
.0
9)
*
0.
31
(0
.1
2)
*
−0
.4
9
(0
.3
1)
0.
49
(0
.0
5)
**
*
−0
.1
3
(0
.0
4)
**
0.
21
(0
.0
5)
**
*
0
a
A
ll
re
su
lts
ar
e
β
co
ef
fi
ci
en
ts
(S
E
)
fr
om
th
e
M
R
in
st
ru
m
en
ta
lv
ar
ia
bl
e
es
tim
at
es
us
in
g
IV
W
an
d
so
re
fl
ec
td
if
fe
re
nc
es
in
m
ea
n
ou
tc
om
e
pe
r
on
e
un
it
di
ff
er
en
ce
of
th
e
ex
po
su
re
s
fo
r
co
nt
in
uo
us
ly
m
ea
su
re
d
ou
tc
om
es
an
d
di
ff
er
en
ce
in
lo
g
od
ds
fo
r
bi
na
ry
ou
tc
om
es
(C
H
D
/ty
pe
2
di
ab
et
es
)
*p
<
0.
05
,*
*p
<
0.
01
,*
**
p
<
0.
00
1
F
I,
fa
st
in
g
in
su
lin
;F
P
G
,f
as
tin
g
pl
as
m
a
gl
uc
os
e;
H
D
L
-C
,H
D
L
-c
ho
le
st
er
ol
;L
D
L
-C
,L
D
L
-c
ho
le
st
er
ol
;T
2D
M
,t
yp
e
2
di
ab
et
es
m
el
lit
us
;T
G
,t
ri
ac
yl
gl
yc
er
ol
s
Diabetologia (2017) 60:2210–2220 2215
our understanding of which CHD risk factors mediate BMI
effects. Our findings provide strong support for undertaking
RCTs in obese people to test the effect of triacylglycerol re-
duction and glycaemic control on CHD risk.
Several MR studies have previously examined the
association of BMI with CHD and CHD risk factors [11, 12,
14, 24, 25]. Our results are broadly consistent with those,
including our finding of no evidence for the causal association
between BMI and LDL-cholesterol [12, 24, 26]. This is
further supported by two RCTs of bariatric surgery which
found that in tens ive weight loss d id not lower
LDL-cholesterol [27, 28]. Consistent with our results,
previous MR studies have also shown positive causal effects
of type 2 diabetes, HbA1c, LDL-cholesterol and
triacylglycerols with CHD [29–32], but not for causal effects
of fasting glucose or HDL-cholesterol with CHD once
horizontal pleiotropy has been accounted for. The discrepancy
between finding a causal effect of type 2 diabetes and HbA1c
on CHD, but not of fasting glucose, might suggest that
non-fasting (postprandial) glucose levels, more so than fasting
levels, are most relevant for CHD risk and/or that long-term
hyperglycaemia (as assessed by elevated HbA1c and likely to
be identified as being above the threshold required to diagnose
type 2 diabetes) are important.
To our knowledge only one previous study has tried to
explore potential mediation of the BMI–CHD effect in an
MR framework. That study included 11,056 individuals with
CHD and 75,627 control participants from Copenhagen and
used only three BMI-related SNPs. It concluded that the effect
of BMI on increased CHD risk was partly mediated through
elevated levels of LDL-cholesterol, non-fasting remnant
cholesterol and systolic BP [14]. The evidence for a mediating
role of remnant cholesterol is entirely consistent with our
findings here for triacylglycerols, as remnant cholesterol is
the cholesterol content of triacylglycerol-rich lipoproteins,
particularly so in this previous study where remnant cholesterol
was not directly measured but estimated from other lipids using
Table 3 MR estimates of BMI (SD, 1 SD = 4.5 kg/m2) on cardio-
vascular risk factors and CHD
Exposure: BMI (n = 322,154) Effect
estimate
95% CI p value
CHD (n = 60,801 case and 123,504 control participants)a
IVW 1.45 1.27, 1.66 < 0.001
Weighted-median 1.44 1.24, 1.67 < 0.001
MR-Egger regression
Slope 1.55 1.26, 1.91 < 0.001
Intercept (directional
pleiotropy)
1.00 0.99, 1.00 0.50
Type 2 diabetes mellitus (n = 34,840 case and 114,981 control
participants)a
IVW 1.96 1.35, 2.83 < 0.001
Weighted-median 2.63 2.16, 3.21 < 0.001
MR-Egger regression
Slope 3.42 2.63, 4.46 < 0.001
Intercept (directional
pleiotropy)
0.98 0.98, 0.99 < 0.001
Fasting glucose, mmol/l (n = 46,186)b
IVW 0.07 0.03, 0.11 < 0.001
Weighted-median 0.08 0.05, 0.12 < 0.001
MR-Egger regression
Slope 0.09 0.036, 0.15 < 0.001
Intercept −0.0007 −0.002, 0.001 0.37
HbA1c, % (n = 46,368)
b
IVW 0.05 0.01, 0.08 0.005
Weighted-median 0.09 0.04, 0.14 < 0.001
MR-Egger regression
Slope 0.09 0.008, 0.16 0.03
Intercept −0.001 −0.003, 0.001 0.31
Fasting insulin, log-pmol/l (n = 38,238)b
IVW 0.18 0.14, 0.22 < 0.001
Weighted-median 0.18 0.12, 0.24 < 0.001
MR-Egger regression
Slope 0.16 0.07, 0.25 < 0.001
Intercept 0.0007 −0.002, 0.003 0.60
LDL-cholesterol, SD (1 SD = 1.0 mmol/l) (n = 188,577)b
IVW −0.05 −0.19, 0.09 0.50
Weighted-median −0.01 −0.08, 0.05 0.66
MR-Egger regression
Slope −0.10 −0.184,
− 0.02
0.02
Intercept 0.0016 −0.001, 0.004 0.19
HDL-cholesterol, SD (1 SD = 0.40 mmol/l) (n = 188,577)b
IVW −0.23 −0.32, −0.15 < 0.001
Weighted-median −0.21 −0.27, −0.16 < 0.001
MR-Egger regression
Slope −0.23 −0.307, −0.15 < 0.001
Intercept −0.0001 −0.002, 0.002 0.90
Table 3 (continued)
Exposure: BMI (n = 322,154) Effect
estimate
95% CI p value
Triacylglycerol, SD (1 SD = 1.024 mmol/l) (n = 188,577)b
IVW 0.20 0.14, 0.26 < 0.001
Weighted-median 0.21 0.15, 0.27 < 0.001
MR-Egger regression
Slope 0.17 0.09, 0.24 < 0.001
Intercept 0.001 −0.001, 0.003 0.37
a Binary outcome—effect estimate is the OR for a 1 SD increase in BMI
b Continuously measured outcome—effect estimate is the difference in
mean in the unit provided in column 1 for a 1 SD increase in BMI
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a method that would produce an extremely high correlation
between (measured) triacylglycerols and estimated remnant
cholesterol; mediation by remnant cholesterol is thus consistent
with mediation by triacylglycerols [14].
Our study, the previous (Copenhagen) study [13, 14], other
MR studies [12, 24, 26] and RCTs of bariatric surgery [33, 34]
have found no evidence for a causal effect of BMI on
LDL-cholesterol, which suggests it is unlikely to be an
important mediator of BMI on CHD. However, since the
previous study (despite finding no MR evidence for a causal
effect of BMI on LDL-cholesterol) concluded that
LDL-cholesterol was a partial mediator [14], we examined
that possibility in our data. As expected we found no strong
support for a mediating effect of LDL-cholesterol between
BMI and CHD (ESM Table 12). We were unable to explore
any mediating effect of BP in our study. This is because our
approach uses publicly available aggregate genome-wide
results and the International Consortium for Blood Pressure
(ICBP) provides information on SNPs and BP associations
without specifying the risk (or effect) allele for each SNP; thus
the effect of BMI on BP cannot be assessed using the
two-sample MR instrumental variable analysis.
CHD is a major cause of morbidity and mortality and its
prevalence is increasing worldwide, partly because of the
increasing prevalence of obesity. Our results indicate the
extent to which acting on risk factors, such as triacylglycerols,
HbA1c and type 2 diabetes, might counteract the detrimental
effects of obesity on CHD. They highlight the potential
importance of using interventions that lower triacylglycerols
and/or HbA1c and type 2 diabetes specifically in those with
obesity [35, 36]. There is evidence, including from MR
studies, that statins affect triacylglycerols and remnant
cholesterol, as well as LDL-cholesterol [37]. Furthermore, a
rare variant in APOC3 with a marked effect on triacylglycerol
levels provides a potential target for drug development aimed
at reducing triacylglycerol levels, independent of any statin
effects [38, 39]. Thus, targets for reducing triacylglycerols
exist and testing the effect of these in obese populations would
be feasible. Previous RCTs have shown that the oral
Table 5 Multivariate separate-sample MR analysis of the effect of
BMI (per SD, 1 SD = 4.5 kg/m2) on CHD
OR 95% CI p value Mediation
effect (%)
MR-IVW regression, crude 1.45 1.27, 1.66 < 0.001
Multivariate model
(1) Adjusted for
triacylglycerol
1.16 0.99, 1.36 0.06 22
(2) Adjusted for HbA1c 1.36 1.19, 1.57 0.001 4
(3) Adjusted for type 2
diabetes
1.35 1.17, 1.56 0.001 –
(4) Adjusted for
triacylglycerol +
HbA1c
1.09 0.94, 1.27 0.25 38
(5) Adjusted for
triacylglycerol + type 2
diabetes
1.10 0.94, 1.29 0.22 –
Table 4 MR estimates of cardiovascular risk factors on CHD
Risk factor OR 95% CI p value
Type 2 diabetes mellitus
IVW 1.12 1.06, 1.18 < 0.001
Weighted-median 1.11 1.05, 1.17 < 0.001
MR-Egger regression
Slope 1.07 0.99, 1.15 0.10
Intercept 1.01 1.00, 1.01 0.17
Fasting glucose, mmol/l
IVW 1.31 1.09, 1.58 < 0.001
Weighted-median 1.21 1.01, 1.44 0.03
MR-Egger regression
Slope 1.08 0.87, 1.35 0.50
Intercept 1.01 1.00, 1.01 0.04
HbA1c, %
IVW 1.30 1.08, 1.56 0.01
Weighted-median 1.36 1.07, 1.74 0.01
MR-Egger regression
Slope 1.66 1.03, 2.68 0.04
Intercept 0.99 0.97, 1.01 0.27
Fasting insulin, log-pmol/l
IVW 2.80 1.89, 4.16 < 0.001
Weighted-median 2.61 1.61, 4.23 < 0.001
MR-Egger regression
Slope 0.49 0.09, 2.59 0.40
Intercept 1.03 1.00, 1.05 0.04
LDL-cholesterol, SD (1 SD = 1.0 mmol/l)
IVW 1.58 1.43, 1.75 < 0.001
Weighted-median 1.63 1.48, 1.80 < 0.001
MR-Egger regression
Slope 1.74 1.59, 1.90 < 0.001
Intercept 0.99 0.98, 0.99 0.01
HDL-cholesterol, SD (1 SD = 0.4 mmol/l)
IVW 0.86 0.78, 0.95 < 0.001
Weighted-median 0.88 0.81, 0.95 < 0.001
MR-Egger regression
Slope 1.03 0.95, 1.12 0.46
Intercept 0.99 0.98, 0.99 < 0.001
Triacylglycerol, SD (1 SD = 1.024 mmol/l)
IVW 1.24 1.10, 1.41 < 0.001
Weighted-median 1.23 1.11, 1.36 < 0.001
MR-Egger regression
Slope 1.13 1.03, 1.24 0.01
Intercept 1.01 1.003, 1.01 < 0.001
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hypoglycaemic metformin reduces cardiovascular risk factors
[40–42] in non-diabetic at-risk populations, including those
who are obese, but its effect on CHD risk has yet to be
established. Our results suggest that i t might be
cardioprotective in populations with high BMI and supports
the development of RCTs to test its effect on CHD in
these people.
Strengths and limitations
Two-sample MR exploits the fact that it is not necessary to
obtain both gene–exposure association (ratio denominator)
and gene–outcome association (ratio numerator) from the
same sample of participants. There are some advantages to
obtaining them from two different sets of participants. For
example, ‘winners’ curse’ [16] can bias true causal effects
towards observational results in one-sample MR but is less
likely to generate false-positive findings in two-sample MR.
In addition, the weak instrument bias, which biases effects
towards the confounded multivariable regression result in
one-sample MR, biases the effect towards the null in
two-sample MR (with non-overlapping datasets). The main
advantage of two-sample MR is the increased statistical
power, particularly in relation to testing effects on binary
disease outcomes (i.e. CHD or type 2 diabetes) because of
the use of summary data from GWAS consortia [16].
Our study is extremely large and uses genetic variants to
avoid some of the key limitations of traditional multivariable
regression approaches to mediation. Horizontal pleiotropy is
one of the major concerns in relation to limitations of MR
studies. However, to explore the potential effects of this
pleiotropy, we used different MR methods (IVW, median-
based estimators and MR-Egger) that have different
assumptions and we assessed the consistency across each of
these estimators. The mediators that we took forward into
MR-based mediation analyses (triacylglycerols, HbA1c and
type 2 diabetes) had consistent causal effects across these
different methods for both steps (i.e. the effect of BMI on them
and of them on CHD). In the mediation analyses, where we
include both genetically predicted triacylglycerols and HbA1c,
we are assuming that these factors are not causally related to
each other. We tested for causal relationships between
potential mediators prior to our main two-step MR analyses
and these do not suggest any causal effects between
triacylglycerols and HbAlc or other glycaemic traits.
However, MR studies cannot completely rule out a causal
relationship between the two. Previous large prospective
studies showed triacylglycerols predicted the development of
type 2 diabetes [43, 44], if this association is casual, the
est imated mediat ion effect by dysglycaemia and
triacylglycerols could be inflated. Our results would be biased
if the mediators we have tested caused variation in BMI
(i.e. there was reverse causality from mediators to BMI). If
this were the case, we would expect a bi-directional MR effect
between BMI and the mediating risk factors. However, we
found no evidence that triacylglycerols or HbA1c caused
variation in BMI (though the causal effect of BMI to these
mediators was present).
Whilst all three MR methods suggest a casual effect of
triacylglycerols on CHD, the MR-Egger intercept suggests
that directional horizontal pleiotropy may be exhibited by
the instruments. It is plausible that the genetic variants we
used as instruments for triacylglycerols also affect other
remnant cholesterols or other lipids and those also contribute
to mediating BMI effects on CHD. Another potential
limitation to our study is that we have assumed no interaction
between BMI andmediators, but we are not able to test for this
because we have used aggregated genome-wide data.
Previous observational studies suggest that the association
between BMI and CHD may be modified by hypertension
[45], but have not found effect modification by the glycaemic
and lipid traits that we have examined here [46]. In two-
sample MR, with independent samples, weak instrument bias
can result in bias towards the null. In mediation analyses this
could result in an underestimation of mediating effects.
However, given our large sample size and the fact that our
genetic instruments explained 2.1% and 2.4% of the variation
in triacylglycerols and HbA1c, respectively, and had very large
first stage F-statistics, we think this is unlikely to have had a
major effect on our results. In addition, there is a partial
overlap in studies that contributed to both GWAS (i.e. some
cohort studies have contributed both to GWAS of exposure
and also of outcomes). Of the 38 studies included in the
CARDIoGRAMplusC4D, 24 appear in GIANT (about 30%
of participant overlap) [47]. In the case of weak instruments,
the sample overlap between the exposure- and outcome-
consortia could bias two-sample MR estimates towards the
confounded association between the exposure and the out-
come [16, 47]. Nevertheless, as we used genetic instruments
strongly associated with our exposure, as suggested by large
F-statistics, it is unlikely that our results were biased by weak
instruments [47].
In conclusion, our results support a causal effect of higher
BMI on CHD risk that is, at least partially, mediated through
the effect of BMI on triacylglycerols, HbA1c and type 2
diabetes. These findings support the need for interventional
studies examining whether lowering triacylglycerols or
providing glucose-lowering therapy for people who are
overweight or obese is effective at reducing their increased
risk (in comparison with people of healthy weight) of CHD.
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